Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three immunosuppressive drugs—azathioprine, cyclosporine, and methylprednisolone—used primarily to prevent organ transplant rejection and to treat certain autoimmune diseases. - **Azathioprine** is a purine analogue antimetabolite that acts as an immunosuppressant by inhibiting DNA and RNA synthesis in proliferating cells, particularly lymphocytes[5][6]. - **Cyclosporine** is a calcineurin inhibitor that suppresses T-cell activation by inhibiting the transcription of interleukin-2 (IL-2) and other cytokines[4]. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties; it modulates gene expression to reduce inflammation and immune responses[1]. This triple-drug regimen is commonly used in solid organ transplantation (such as kidney transplants) to prevent graft rejection by targeting multiple pathways of the immune response. It may also be used for severe autoimmune conditions when monotherapy or dual therapy are insufficient[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azathioprine + cyclosporine + methylprednisolone.